Get the latest news on Somaxon. Click any link to retrieve the press release in PDF format. (Adobe Acrobat Reader is required). If you don’t have Adobe Acrobat, download it for free from Adobe.
June 13, 2008, SOMAXON PHARMACEUTICALS APPOINTS ERLE T. MAST AND THOMAS G. WIGGANS TO ITS BOARD OF DIRECTORS
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced the appointments of Erle T. Mast and Thomas G. Wiggans as independent directors of the company. In addition, Mr. Mast will serve as chairman of the company's audit committee, and Mr. Wiggans will serve as a member of the company’s nominating/corporate governance committee. (,pdf)
June 12, 2008, SILENOR™ DATA PRESENTED AT THE 22nd ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES
-- New data analysis shows significant symptom improvements with SILENOR™
in elderly adults with chronic insomnia --
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that data from three Phase 3 clinical trials of the company’s product candidate SILENOR™ (doxepin HCl) for the treatment of insomnia were presented this week at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, Maryland. (.pdf)
June 6, 2008, Somaxon Pharmaceuticals to Present
at the Needham & Co. 7th Annual Biotechnology and Medical
Technology Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that Susan Dubé, senior vice president, corporate development, will present
a company overview at the Needham 7th Annual Biotechnology and Medical Technology
Conference at the New York Palace Hotel in New York City, on Thursday, June 12, 2008 at
1:00 p.m. ET (10:00 a.m. PT). (.pdf)
June 4, 2008, SOMAXON PHARMACEUTICALS TO PRESENT DATA AT THE 22nd ANNUAL MEETING OF THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES
-- Researchers to present data from Phase 3 clinical trials
of SILENOR™ (doxepin HCl) for the treatment of insomnia --
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a
specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that one oral presentation and four posters including data from the company’s Phase 3 clinical trial program of its lead drug candidate SILENOR™ (doxepin HCl) for the treatment of insomnia will be presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, Maryland.(.pdf)
May 22, 2008, SOMAXON PHARMACEUTICALS SECURES UP TO
$65 MILLION IN FINANCING
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced that it has entered into a $15 million secured loan agreement with Oxford Finance
Corporation and Silicon Valley Bank and a Committed Equity Financing Facility (CEFF) with
Kingsbridge Capital Limited in which Kingsbridge has committed to provide up to $50 million of
capital through the purchase of newly-issued shares of Somaxon’s common stock. (.pdf)
May 22, 2008, Somaxon Pharmaceuticals to Present
at the FBR Capital Markets 12th Annual
Spring Investor Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that David Hale, executive chairman and interim chief executive officer,
will present a company update at the FBR Capital Markets 12th Annual Spring Investor
Conference at the Grand Hyatt Hotel in New York, on Thursday, May 29, 2008 at 8:15 a.m.
ET (5:15 a.m. PT). (.pdf)
May 7, 2008, CLINICAL DATA ON SOMAXON PHARMACEUTICALS’ PRODUCT CANDIDATE FOR THE TREATMENT OF INSOMNIA PRESENTED AT AMERICAN PSYCHIATRIC ASSOCIATION ANNUAL MEETING
- Data presented from three Phase 3 clinical trials of the company’s product candidate SILENOR™ (doxepin HCl) for the treatment of insomnia
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that data from three Phase 3 clinical trials of the company’s product candidate SILENOR™ (doxepin HCl) for the treat- ment of insomnia were presented today at the American Psychiatric Association (APA) 161st annual meeting in Washington, D.C. (.pdf)
May 6, 2008, SOMAXON PHARMACEUTICALS REPORTS
2008 FIRST QUARTER FINANCIAL RESULTS
- First quarter 2008 net loss of $7.1 million, or $0.39 per share, vs. $6.9 million, or $0.38 per
share, in 2007 first quarter
- New Drug Application (NDA) submission for SILENOR™ (doxepin HCl) accepted for review
by the U.S. Food and Drug Administration (FDA) as of March 31, 2008
- Conference call scheduled today at 1:30 p.m. PT; Simultaneous webcast at http://investors.somaxon.com/events.cfm
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced financial results for the first quarter ended March 31, 2008. (.pdf)
May 2, 2008, SOMAXON PHARMACEUTICALS ANNOUNCES DATA TO BE PRESENTED
AT AMERICAN PSYCHIATRIC ASSOCIATION 161st ANNUAL MEETING
- Researchers to present data from three Phase 3 clinical trials of
doxepin for the treatment of insomnia
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a
specialty pharmaceutical company focused on the in-licensing and development of proprietary
product candidates for the treatment of diseases and disorders in the fields of psychiatry and
neurology, today announced that four posters including data from three Phase 3 clinical trials of
the company’s product candidate, doxepin for the treatment of insomnia, will be presented at the
American Psychiatric Association (APA) 161st annual meeting in Washington, DC on
Wednesday, May 7, 2008 from 12pm to 2pm ET. Data from these posters is embargoed until they
are presented. (.pdf)
April 29, 2008, Somaxon Pharmaceuticals to Report 2008 First Quarter Results
and Host Conference Call on May 6, 2008
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that it will release its 2008 first quarter financial results after the market closes on Tuesday May 6, 2008. Somaxon management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer questions.
The conference call will be available to interested parties through a live audio Internet broadcast on the Somaxon website. More details are contained in the press release. (.pdf)
April 25, 2008, Somaxon Pharmaceuticals to Present
at the Morgan Stanley Global Healthcare
Unplugged Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday May 1, 2008 at 5:00 p.m. EDT. The conference will take place at the Ritz-Carlton Hotel in Key Biscayne, Florida. (More details, pdf)
A live webcast of the presentation will be available in the Investor Relations section of the company’s website under Event Scheduler.
April 15, 2008, SOMAXON PHARMACEUTICALS ANNOUNCES ACCEPTANCE
FOR FILING OF NEW DRUG APPLICATION FOR
SILENOR™ FOR THE TREATMENT OF INSOMNIA
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has
accepted for filing the company's New Drug Application (NDA) for SILENOR™ (doxepin
hydrochloride). Somaxon is seeking marketing approval of SILENOR™ for the treatment of
insomnia. (.pdf)
March 18, 2008, Somaxon Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare Conference
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the Cowen and Company 28th Annual Healthcare Conference at The Boston Marriott Copley Place Hotel, in Boston, on Tuesday, March 18, 2008, at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time). (.pdf)
March 11, 2008, SOMAXON REPORTS 2007 FULL YEAR FINANCIAL RESULTS
Conference call scheduled today at 1:30 p.m. PT; Simultaneous webcast
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty
pharmaceutical company focused on the in-licensing and development of proprietary product
candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today
announced financial results for the fourth quarter and full year ended December 31, 2007. (.pdf)
March 6, 2008, Somaxon Pharmaceuticals to Report 2007 Fourth Quarter and
Full Year Financial Results and Host Conference Call
on March 11, 2008
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX)
today announced that it will release its 2007 fourth quarter and full year financial results after the
market closes on Tuesday March 11, 2008. Somaxon management will host a conference call
that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to review the financial results and answer
questions. (.pdf)
January 31, 2008,
SOMAXON PHARMACEUTICALS SUBMITS
NEW DRUG APPLICATION FOR
SILENOR™ FOR THE TREATMENT OF INSOMNIA
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SILENOR™ (doxepin hydrochloride). Somaxon is seeking marketing approval of SILENOR™ for the treatment of insomnia. (.pdf)
January 9, 2008,
SOMAXON PHARMACEUTICALS ANNOUNCES COMPLETION OF 26-WEEK TRANSGENIC MOUSE CARCINOGENICITY STUDY OF SILENOR™
• SILENOR™ NDA submission planned by mid-February 2008
SAN DIEGO, CA – Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that it has completed a 26-week transgenic mouse carcinogenicity study of doxepin, the active pharmaceutical ingredient in its product candidate SILENOR™. Based on the results of this study and a review of such results with its consultant toxicologists, Somaxon intends to proceed with the submission of a New Drug Application for SILENOR™, which is now estimated to occur by mid-February 2008. (.pdf)
January 3, 2008, Somaxon Pharmaceuticals to Present at JP Morgan 26th Annual Healthcare Conference
SAN DIEGO, CA –Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the JP Morgan 26th Annual Healthcare Conference at The Westin St. Francis, San Francisco, on Thursday, January 10, 2008, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). A live webcast of the event will be available. (.pdf)
